Rapid Diagnostic Test

First Enzymatic Point of Care

For Tuberculosis

Innovation

Pulmonescence Diagnostics is developing a low-cost and point-of-care triage diagnostic test for Tuberculosis that would help health-care staff identify patients with Tuberculosis that may need further tests and treatment.

Our technology called Reporter Enzyme Fluorescence (REF) uses substrate-enzyme reactions generating a fluorescent signal in the presence of the enzyme produced by the bacterium of TB. This technology is a rapid, low-cost test that will help diagnosed in less time than current technologies. 

Tuberculosis

Tuberculosis (TB) is the world’s top infectious killer caused by the bacteria Mycobacterium tuberculosis.

TB diagnosis is critical to help patients with Tuberculosis get the treatment they need. Globally, about 10 million people get infected with TB every year, and it is one of the top causes of death and the leading cause from a single infectious agent (above HIV/AIDS).

Some symptoms of active lung TB are cough with sputum and blood,  chest pain, and fever.

x-ray of chest show cavity at right lung and interstitial infiltrate both lung due to TB infection
Right lung: Chest x-ray showing TB infection and pulmonary TB

Who we are?

Pulmonescence Diagnostics was founded by experienced entrepreneurs on TB diagnostics with the mission to create an inexpensive, simple, sputum-based point-of-care (POC) for Drug Susceptibility Testing.

Our team has extensive experience developing early-stage companies and translating technology emerging from academia.

Our Research

Our research has been the pathogenesis of bacterial lung infections including tuberculosis. Read our publications to learn more about our technology and tuberculosis disease.